GSK’s Jemperli recommended by NICE for endometrial cancer treatment
Betsy Goodfellow | March 5, 2024 | News story | Medical Communications | GSK, Jemperli, NICE, Oncology, endometrial cancer
GSK has announced that the National Institute for Health and Care Excellence (NICE) has recommended the use of Jemperli (dostarlimab) in combination with platinum-containing chemotherapy.
The drug is recommended for the treatment of adult patients with mismatch repair deficient (dMMR)/microsatellite instability-high (MSI-H) primary advanced or recurrent endometrial cancer, and who are eligible for systemic therapy.
Following this recommendation, the company is working with the relevant UK health authorities, including the Scottish Medicines Consortium, in order to provide access to the drug to those who may benefit from the treatment in a first-line setting.
Jack Harris, vice-president UK Oncology at GSK, commented: “At GSK, we aspire to get ahead of cancer and improve outcomes for people living with the devastating reality of a diagnosis. Today’s decision is an important step forward, and a testament to our ongoing commitment to driving innovation for people with unmet needs, providing patients with the opportunity to access this treatment in the first line treatment setting. While today’s news is specific to endometrial cancer, our commitment in oncology extends to difficult to treat solid tumours and haematological malignancies. We have seen great developments within our pipeline over the last year and we are proud to have contributed to meaningful advancements in oncology.”
Dr Chloe Barr, specialist registrar, trustee and advocacy lead at Peaches Womb Cancer Trust, added: “This new treatment for primary advanced or recurrent dMMR/MSI-H endometrial cancer will provide options for people currently facing the reality of very few effective anti-cancer treatments. This decision is very welcome news and we hope that this is just the first step towards wider availability of more effective first-line treatment options for those affected by this devastating cancer.”
Betsy Goodfellow
Related Content
GSK’s Jemperli accepted for FDA review for endometrial cancer treatment
GSK has announced that the US Food and Drug Administration (FDA) has accepted its supplemental …
GSK shares results from phase 3 trial for gonorrhoea treatment
GSK has announced positive results from its phase 3 EAGLE-1 trial for gepotidacin, a potential …
GSK’s meningococcal vaccine candidate accepted for FDA review
GSK has announced that the US Food and Drug Administration (FDA) has accepted for review …
